NCT04906330 is a clinical trial of Oncoliq: test for early breast cancer detection. in Breast Cancer, sponsored by Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich.

Who is sponsoring NCT04906330?

NCT04906330 is sponsored by Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich.

What drugs are being tested in NCT04906330?

Interventions in NCT04906330: Oncoliq: test for early breast cancer detection..

What condition does NCT04906330 study?

NCT04906330 studies Breast Cancer.

Is NCT04906330 still recruiting?

NCT04906330 is currently status unknown. Last updated 28 February 2024.

Last reviewed 2024-02-28 · How we verify

NCT04906330

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oncoliq: Test for Early Breast Cancer Detection.

Status unknown Last updated 28 February 2024

What this trial tests

trial testing Oncoliq: test for early breast cancer detection. in Breast Cancer in 500 participants. Status unknown.

Timeline

1 September 2021

Primary endpoint
1 August 2024

1 August 2025

Quick facts

Lead sponsor	Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 September 2021
Primary completion	1 August 2024
Estimated completion	1 August 2025
Sites	1 location across Argentina

Drugs / interventions tested

Oncoliq: test for early breast cancer detection.

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich

Who can join

Adults 50 to 70, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Oncoliq is a novel early breast cancer detection test based on liquid biopsies and microRNAs. This innovative test will allow improving the accuracy of cancer detection which will impact on health, reducing the patient mortality and health costs. To develop this test, it has been finished the preclinical PHASE I: in laboratory animals; PHASE II: exploratory clinical phase for the discovery of candidate biomarkers in breast cancer patients and PHASE III: clinical validation of biomarkers showing that Oncoliq has 91% of sensitivity. Currently it is been setting up a "pilot test" for breast cancer to enrol 500 woman volunteers without previous cancer diagnosis that go to the annual medical control. The results of the pilot test will give the accuracy for early breast cancer detection.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives.
Seif F, Torki Z, Zalpoor H, Habibi M, et al · · 2023 · cited 31× · PMID 36816749 · DOI 10.1016/j.omto.2023.01.001
Addressing the Clinical Feasibility of Adopting Circulating miRNA for Breast Cancer Detection, Monitoring and Management with Artificial Intelligence and Machine Learning Platforms.
Ling L, Aldoghachi AF, Chong ZX, Ho WY, et al · · 2022 · cited 12× · PMID 36499713 · DOI 10.3390/ijms232315382
Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications.
Beňačka R, Szabóová D, Guľašová Z, Hertelyová Z. · · 2024 · cited 7× · PMID 39795985 · DOI 10.3390/ijms26010127
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer.
Gianni C, Palleschi M, Merloni F, Bleve S, et al · · 2022 · cited 4× · PMID 36612091 · DOI 10.3390/cancers15010096
Ambivalent roles of miRNAs in cancer development via modulating tumor-associated innate immune cells.
Naseri B, Mardi A, Shekari N, Shajari N, et al · · 2025 · PMID 41409584 · DOI 10.34172/bi.31430

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04906330 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich
Last refreshed: 28 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04906330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing